512.14MMarket Cap-4.96P/E (TTM)
6.675High6.200Low3.37MVolume6.245Open6.420Pre Close21.78MTurnover4.42%Turnover RatioLossP/E (Static)77.01MShares12.35052wk High4.15P/B507.70MFloat Cap5.27552wk Low--Dividend TTM76.35MShs Float978.000Historical High--Div YieldTTM7.40%Amplitude-1731.000Historical Low6.461Avg Price1Lot Size
Altimmune Stock Forum
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet